

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-Blind, Placebo-Controlled Trial

J Michael Gaziano ¹, Carlos Brotons ², Rosa Coppolecchia ³, Claudio Cricelli ⁴, Harald Darius ⁵, Philip B Gorelick ⁶, George Howard ⁷, Thomas A Pearson ⁸, Peter M Rothwell ⁹, Luis Miguel Ruilope ¹⁰, Michal Tendera ¹¹, Gianni Tognoni ¹², ARRIVE Executive Committee

¹Brigham and Women's Hospital, Department of Medicine, Division of Aging, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; VA Boston Healthcare System, Boston, MA, USA. Electronic address: jmgaziano@partners.org.

²Sardenya Primary Health Care Center, EAP Sardenya-Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.

³Bayer HealthCare LLC, Whippany, NJ, USA.

⁴Società Italiana di Medicina Generale, Florence, Italy.

⁵Department of Cardiology, Angiology, Nephrology and Intensive Care Medicine, Vivantes Neukoelln Medical Center, Berlin, Germany.

⁶Department of Translational Science & Molecular Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA; Vascular Neurology Program, Mercy Health Hauenstein Neurosciences, Grand Rapids, Michigan Grand Rapids, MI, USA.

⁷Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.

⁸Department of Epidemiology and Medicine, University of Florida Health Science Center, Gainesville, FL, USA.

⁹Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

¹⁰Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain.

¹¹Department of Cardiology and Structural Heart Disease, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.

¹²IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Department of Cardiovascular Research, IRCCS, Milan, Italy.